910-22 Mitral Regurgitation (not Restenosis) is the Most Frequent Indication for Valve Replacement After Balloon Mitral Valvotomy
| Autor: | Gerald Dorros, Donald A. Rothbaum, David T. Kawanishi, David R. Holmes, Gregory S. Pavlides, John D. Carroll, Larry S. Dean, Ted Feldman, Igor F. Palacios, Howard C. Herrmann |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
medicine.medical_specialty
Mitral regurgitation Balloon mitral valvotomy business.industry viruses medicine.medical_treatment Mitral valve replacement food and beverages medicine.disease Surgery Valve replacement Restenosis Internal medicine medicine Cardiology business Mitral area Cardiology and Cardiovascular Medicine |
| Zdroj: | Journal of the American College of Cardiology. 25(2) |
| ISSN: | 0735-1097 |
| DOI: | 10.1016/0735-1097(95)91719-e |
| Popis: | The indications for mitral valve replacement (MVR) after balloon mitral valvotomy (BMV) remain poorly characterized. Restenosis has been the focus of most concerns regarding the long-term need for re-BMV or MVR. We reviewed the indications for MVR after BMV in 770 patients during 3 years. Indication for MVR: l 30 days (n = 34) g 30 days (n = 47) Restenosis 0 15% CHF 0 30% Failed BMW 15% 9% MR 85% 46% MVR was necessary in 4.5% within 30 days of BMV The indication for MVR was mitral regurgitation (MR) in 3.8% and failed BMV in 0.7%. Late MVR (more than 30 days post BMV) was done in an additional 6.1%. MVR was most frequently necessary for increasing MR or symptoms due to mixed or multiple valve lesions (p l 0.001). Restenosis (loss of half the initial gain in mitral area) accounted for only 15% of the indications for MVR. Conclusion Restenosis is an infrequent indication for MVR after BMV. Other factors including initially insufficient enlargement of the mitral orifice, persistent symptoms, and progression of post-BMV MR are the major indications for MVR after balloon mitral valvotomy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|